Confidential · NDA required
Investor document package
The controlling Bridge Investor Subscription Binder and three supporting documents are released only to prospective investors who accept the non-disclosure agreement below. The binder controls if any website summary or supporting document conflicts with it.
Read first — Non-Disclosure Agreement
By entering this page, you are agreeing to the terms and conditions of the NDA set out below, and to keep all Trocar Pharma materials strictly confidential.
This Confidentiality and Non-Disclosure Agreement (the “Agreement”) is entered into as of the date of your electronic acceptance, between Trocar Pharma, Inc., a Delaware corporation, and you, individually and on behalf of any entity you represent (the “Recipient”).
1. Confidential Information
“Confidential Information” means the Bridge Investor Subscription Binder, its supporting documents, and every exhibit, financial model, scientific dataset, regulatory correspondence, patent or license detail, projection and communication made available to you by Trocar Pharma, Inc. (“Trocar”) in connection with its financing, whether marked confidential or not.
2. Permitted Use
You may use the Confidential Information solely to evaluate a possible investment in Trocar. You may not use it to compete with Trocar, to trade in any security, or for any other purpose.
3. Non-Disclosure
You will not disclose, publish, forward, post, or reproduce the Confidential Information, in whole or in part, to any person other than your own directors, officers, employees, and professional advisors who need it to evaluate the investment and who are bound by confidentiality obligations at least as protective as these. You are responsible for any breach by those persons.
4. No Offer; No Reliance
The Memorandum is provided for information only and is not an offer to sell or a solicitation of an offer to buy securities. Any offering is made solely through the Private Placement Memorandum and related governing documents to verified accredited investors under Regulation D, Rule 506(c). Trocar makes no representation or warranty as to the accuracy or completeness of the Confidential Information, and you will rely solely on your own investigation and on the definitive offering documents.
5. Forward-Looking Statements
Projections, market sizes, timelines, and preclinical results are illustrative and are not forecasts. Preclinical data are not predictive of clinical outcomes, and no Trocar product has been approved by the FDA.
6. Return or Destruction
On written request from Trocar, you will promptly destroy or return all copies of the Confidential Information, including electronic copies, except copies retained under mandatory records-retention rules, which remain subject to this agreement.
7. Term, Remedies & Governing Law
These obligations continue for three (3) years from the date of acceptance. You agree that money damages may be inadequate and that Trocar is entitled to seek injunctive relief. This agreement is governed by the laws of the State of Maryland, without regard to conflict-of-law rules, and is executed electronically under the E-SIGN Act.
Questions about this Agreement may be directed to invest@trocarpharma.finance or 702-929-9226.